IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

Articles tagged with “actinium-225-supply-constraints”

Radioligand Therapy Manufacturing Capacity: The CDMO Crunch

A 2026 data report on radioligand therapy manufacturing capacity, covering Novartis's $23 billion US build-out, the CDMO landscape, and the lutetium-177 and actinium-225 isotope supply constraints limiting patient access.

41 min read

8/6/2026

radioligand therapy manufacturing capacity radioligand therapy cdmo isotope supply chain radiopharmaceuticals lutetium-177 supply shortage actinium-225 supply constraints radiopharmaceutical manufacturing targeted radionuclide therapy radiopharma contract manufacturing